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Objective: The purpose of this study was to assess the 
psychometric properties of the Patient Perception of
Migraine Questionnaire (PPMQ), which measures patient
satisfaction with migraine therapy.
Methods and Data: The PPMQ was administered to 940
patients as part of a 3-month, multinational, open-label,
clinical trial comparing the effects of oral naratriptan
2.5 mg with the patient’s customary therapy for the treat-
ment of migraine. Psychometric properties of the PPMQ
were evaluated in terms of its latent factor structure,
validity, reliability, sensitivity, and development of a
scoring method. Classical Test theory and Item Response
theory (IRT) modeling were both used to measure 
reliability.
Results: The PPMQ was able to detect treatment differ-
ences (P > .001), and all items signiﬁcantly correlated
with diary ratings of headache pain (r = .18-.51,
p > .0001) and the Medical Outcomes Short Form-36
pain scale (r = .27, p > .0001). A principal components
factor analysis revealed that the items on the PPMQ were
psychometrically distinct and unidimensional (loadings,
0.74–0.91), with the exclusion of two items. The relia-
bility (i.e., internal item consistency) of the PPMQ post-
trial was high in both treatment groups (Cronbach’s 
a = 0.96). An IRT analysis also ensured the formation of
homogenous items, which were stable on repeat admin-
istration. Items did not require weighting and can be
simply summed to yield a total score.
Conclusion: Based on the data from this one clinical trial,
the 15-item PPMQ was shown to be a valid and reliable
instrument that seems to efﬁciently and comprehensively
measure patient perception of drug attributes in relation
to the treatment of symptoms associated with migraine
headaches.
Keywords: Patient Perception of Migraine Question-
naire, psychometric validation, migraine, satisfaction, 
naratriptan.
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ABSTRACT
Introduction
While some individuals may not have the requisite
clinical knowledge to judge the quality of drug
therapy, nearly all patients have expectations about
the medication that their physician prescribes for
them. If the experience meets or exceeds that expec-
tation, then the patient is usually satisﬁed. Con-
versely, if the experience does not match the
expectation, then the patient is likely to be dissatis-
ﬁed. Dissatisﬁed patients in the United States are
often noncompliant, often delay seeking medical
care, are quick to quit medical insurance plans, and
often lack continuity of care due to “doctor shop-
ping” or continuous switching of their primary
physician [1]. Thus, patient satisfaction has become
an important benchmark to gauge the quality of
health care.
Although satisfaction with health-care delivery
and patient–provider relationships has been exten-
sively studied, there are few studies that directly
measure patient satisfaction with drug therapy.
Pharmaceutical development would likely beneﬁt
from an effort to develop questionnaires that effec-
tively measure satisfaction with treatment, because
patient satisfaction with a medication may play an
important role in the selection, utilization, and ulti-
mate effectiveness of that treatment. To be used
appropriately, however, such questionnaires must
ﬁrst be standardized, which requires assessment of
their validity and reliability.
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Research shows that how well a drug works,
how safe it is, how fast it works, and side effects
are important key attributes of drug therapy for the
treatment of migraine headaches [2]. An additional
study concluded that complete pain relief, no
migraine recurrence, rapid onset, no side effects,
and relief of associated symptoms are important
attributes for the acute treatment of migraine
attacks [3]. We used this information in the devel-
opment of the Patient Perception of Migraine Ques-
tionnaire (PPMQ), which was designed to measure
patient satisfaction with migraine therapy. This
study evaluated the PPMQ’s psychometric proper-
ties: latent factor structure, validity, reliability, and
sensitivity. The PPMQ was administered as part of
a multinational clinical study comparing the effects
of the new migraine treatment naratriptan with that
of the patient’s customary migraine therapy. If sat-
isfaction with drug therapy can be determined reli-
ably with the PPMQ, it is hoped that this may then
translate into earlier and closer to optimal clinical
outcomes for patients with migraine, with sec-
ondary beneﬁts to both the health-care provider and
the insurers.
Methods
Study Design
Data were collected as part of an open-label, ran-
domized, parallel-group clinical trial comparing 3
months of treatment with oral naratriptan 2.5mg
(n = 481) with the patient’s customary therapy
(n = 474) in six countries: Spain, New Zealand, the
Netherlands, Hungary, Finland, and Canada [4].
Treatment for the control group included one or
more customary therapies, excluding any 5-HT1B/1D
receptor agonists. Subjects received a diagnosis of
migraine according to the International Headache
Society criteria. Patients rated the level of pain from
onset of each migraine to relief on a 4-point pain
scale (0 = none; 1 = mild; 2 = moderate; 3 = severe)
and reported their pain assessment on a diary card.
The primary measure of efﬁcacy was the relief of
headache, deﬁned as a reduction of patient-rated
pain from moderate or severe to mild or none,
4 hours after dosing with naratriptan. A widely
used, general health-related quality of life question-
naire, the Medical Outcomes Short Form-36 (SF-
36) [5], was administered in addition to the PPMQ
at baseline and at 3 months post-trial.
PPMQ
The PPMQ was based on an earlier questionnaire
(Migraine Treatment Questionnaire), which was
developed to assess the impact of migraine and
migraine pharmacotherapy on patients. This origi-
nal questionnaire was pretested in a sample of 24
patients with migraine who were participating in 
a clinical trial. Based on participants’ comments,
further modiﬁcations were made to the question-
naire, resulting in a 7-item questionnaire with a 5-
point Likert-type response scale. Analysis after the
piloting of this 7-item questionnaire in a clinical
trial indicated that further reﬁnements to the ques-
tionnaire were necessary. A series of three focus
groups (10–15 patients in each) and 15 patient
interviews resulted in several modiﬁcations of the
questionnaire including addition of 8 new items,
changes to existing items, and a change from a 5-
to a 7-point response scale. During the focus groups
and patient interviews, patients were asked to rank
each of the items in terms of importance. Those
attributes deemed to be of greatest importance (i.e.,
at least 75% of patients ranked the attribute as
important to very important) were considered the
“core” questions (items 1a–2a), and the remaining
7 items were considered optional or could be incor-
porated into studies as needed.
The present trial was conducted in six countries,
and the 15-item PPMQ was translated from the
original English version forward and backward into
the appropriate languages and was administered at
baseline and post-trial [6]. Baseline instructions
stated that patients should respond to questions in
the PPMQ based on their experience with previous
therapy. At the protocol scheduled 3-month post-
trial visit, patient responses were based on treat-
ment for migraine headache administered within
the previous 3 months. The ﬁrst 8 items of the
PPMQ (Appendix A) were recorded on a 7-point
summated rating Likert-type scale (very dissatisﬁed
to very satisﬁed), and responses for the remaining 7
items were recorded on customized 5-point sum-
mated Likert-type rating scales.
Data Analysis
Only subjects completing both study visits were
included in the analyses that depended on the data
from these visits. All statistical tests were conducted
in the intent-to-treat population using “last 
observation carried forward” methodology, which
accounts for dropouts in both treatment arms with
alpha set at 0.05, and two-tailed P values are
reported. A descriptive analysis was performed 
initially to evaluate the mean scores of individual
items, the standard deviation, the variance, fre-
quency of responses, and a summary of missing
data at baseline and at post-trial. The data were
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then evaluated for latent factor structure, validity,
reliability, and sensitivity. Because a problem in
translation existed in Hungary for item 2g of the
PPMQ, data from Hungary were excluded from all
analyses.
The latent factor structure of the PPMQ was
evaluated using a principal components varimax
rotated and oblique rotated analysis using SAS
(version 6.12, 1990; SAS Institute, Inc., Cary, NC,
USA). To determine the number of factors within a
scale, Kaiser’s eigenvalue rule [7] was used, which
states that any factor with an eigenvalue greater
than 1.0 should be considered important when
accounting for item variability. Item loadings of 0.3
and above are considered signiﬁcant [8].
To assess validity of the PPMQ, or its ability to
discriminate between the two treatment groups,
treatment comparisons were performed using a
two-tailed Students’ t test of the mean differences
in baseline and post-trial PPMQ scores. Validity of
the individual items was determined using analysis
of covariance, adjusted for country, of the mean
change from baseline to the end of the 3-month
treatment period for each item in each treatment
group. Additionally, a subgroup analysis of
patients—those who experienced less than six
migraine attacks and those who experienced more
than six migraine attacks—was performed. Validity
was also measured with the Pearson correlation
coefﬁcients between each item of the PPMQ and
pain scores from diary cards, between the total
score of the PPMQ and pain scores from diary
cards, and between selected items on the PPMQ and
SF-36.
To measure the reliability of the PPMQ, Classi-
cal Test theory (CTT) and Item Response theory
(IRT) modeling were used. IRT is a nonlinear prob-
abilistic model that speciﬁes a relationship between
observable patient response and the patient’s under-
lying feelings, as reﬂected by a questionnaire score
[9]. The purpose of our IRT analysis was to model
the interaction between the choice of a patient’s
item response and the patient’s level of satisfaction.
Thus, the standard error is dependent and based on
each patient’s perception. In CTT, the standard
error is a constant value determined by the distrib-
ution of the sample and is assumed to be the same
for everyone in the sample; individual differences
among items or subjects are treated as random error
[7]. Item internal consistency in the CTT analysis
was considered satisfactory if the correlation
between an item and its hypothesized scale was at
least 0.40 [10]. Reliability of the PPMQ was eval-
uated using Cronbach’s alpha coefﬁcient, which
yielded a coefﬁcient of ≥ 0.7 [7], evidence of the
instrument’s reliability.
Three parameters (theta, alpha, beta) were used
in the IRT analysis, using MULTILOG software
(Version 6.0, 1991; Scientiﬁc Software Interna-
tional, Inc., Lincolnwood, IL, USA), to examine the
distribution of responses and the response charac-
teristics of individual items or internal consistency
reliability [9]. The scale of latent satisfaction is
deﬁned by setting the mean of the distribution of
the examined treatment groups to 0, and the stan-
dard deviation is set to 1 for standard IRT analysis.
When comparing parameters from two different
groups, the parameters of both groups must be mea-
sured on the same scale. In our model, theta repre-
sents the subject’s level of satisfaction, predicting
the probability of choosing a given response for a
speciﬁc item. Alpha represents the degree of dis-
crimination that the item provides between persons
at different levels of satisfaction or theta. Items for
which alpha is less than 0.7 are rarely of any prac-
tical value and are not considered to be measuring
satisfaction [11]. The beta parameter represents 
a subject’s threshold of satisfaction or the point 
at which the subject’s experience with the drug
therapy meets the subject’s expectation. The
number of threshold parameters is the number of
response categories minus 1, because the thresholds
deﬁne the point at which subjects are equally likely
to choose adjacent response items. Item thresholds
need to be well distributed to distinguish between
lower and higher levels of satisfaction. Beta para-
meter estimates typically range from about -2.0
(very dissatisﬁed) to +2.0 (very satisﬁed) [9].
Sensitivity, or responsiveness, of our instrument
was measured in two ways: the difference between
baseline and post-trial mean total PPMQ scores was
calculated for each country to assess whether the
instrument could discriminate within treatment
groups, and the difference between pre- and post-
trial pain severity scores from patient diaries as
described above was calculated for each migraine
attack and the mean calculated for each individual
over the 3-month treatment period. These mean dif-
ferences in pain scores were then plotted against the
total post-trial PPMQ scores for each patient.
Results
The mean age of the overall sample (N = 793) at
baseline was 38.4 years; 85% were female and 98%
were white, which reﬂects multinational prevalence
data [12]. The number of patients in each treatment
group was approximately the same in each country,
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and treatment groups had similar sex and age dis-
tributions (Table 1). At baseline, the average length
of time that a subject had experienced migraines
was 18.1 years in the naratriptan group and
17.4 years in the customary therapy group. Over
the 3-month clinical trial period, the average
number of migraine attacks was similar in the two
treatment groups within each country. A summary
report of acute migraine medication use before
entering the study indicated that acetaminophen
(26%), ibuprofen (20%), other nonsteroidal drugs
(26%), and aspirin (6%) were the most commonly
used medications in each treatment group. Cus-
tomary therapy during the trial was most frequently
nonsteroidal anti-inﬂammatory drugs (43%), anal-
gesics (24%), and ergot alkaloids (11%).
The variances for each item on the PPMQ were
approximately equal at baseline and post-trial, 
and the distribution of responses for each item was
only slightly skewed to the right at baseline, with
minimal ceiling (<13%) and ﬂoor (<10%) effects.
Because the data were normally distributed, the
data for each country were pooled for the analyses.
Latent Factor Structure
The initial principal components analysis with a
varimax rotation indicating a two-factor solution is
summarized in Table 2. Factors 1 and 2 explained
62% and 11% of the total variance, respectively.
All of the items loaded relatively high on the factor
1 solution, except item 1d (“how drowsy the drug
makes you”) and item 2g (“how easy the drug was
to use”) for the sample of all countries combined as
well for each individual country, except Spain. An
oblique rotation also yielded a similar solution as
the varimax rotation. The interfactor correlation
for the oblique rotation was 0.39. Loadings on
factor 2 were high with both rotations for only
items 1d and 2g, but face validity suggests that these
items do not appear to be measuring a common
latent variable. For Spain, item 2f (prevents recur-
rence) loaded on factor 2 in addition to item 1d and
2g.
Validity
The PPMQ demonstrated construct validity in that
it was able to detect treatment differences at the end
of the study when data from all countries were com-
bined into one sample. The change in mean PPMQ
total scores from baseline to post-trial was statisti-
cally signiﬁcant in the naratriptan group (P = .0001)
but not in the customary therapy group (P = .884),
indicating greater satisfaction with naratriptan than
with customary therapy. As summarized in Table 3,
changes in mean scores from baseline to post-trial
of each individual item were also signiﬁcantly dif-
ferent (P < .001) when the naratriptan group was
compared to the group receiving customary therapy.
Some subjects may not have treated a sufﬁcient
Table 1 Patient demographics at baseline
Country Characteristic Naratriptan Customary therapy
Canada No. of patients 114 110
Mean age, years (SD) 40.2 (8.7) 39.0 (9.9)
Women (%) 88 86
Finland No. of patients 98 98
Mean age, years (SD) 36.7 (10.7) 36.8 (10.8)
Women (%) 86 87
The Netherlands No. of patients 65 62
Mean age, years (SD) 37.9 (9.6) 41.7 (12.1)
Women 88 82
New Zealand No. of patients 59 55
Mean age, years (SD) 39.6 (10.6) 41.3 (10.0)
Women (%) 73 75
Spain No. of patients 61 64
Mean age, years (SD) 36.2 (9.1) 33.0 (9.2)
Women (%) 84 81
Table 2 Latent factor structure: principal components with
varimax rotation (N = 650)
Item Factor 1 Factor 2
Pain relief (1a) 0.907 0.171
Other symptoms relieved (1b) 0.818 0.190
Speed of relief (1c) 0.873 0.199
Drowsiness (1d) 0.276 0.678
Length of time it works (1e) 0.852 0.244
No. of doses (1f) 0.866 0.202
Return to activities (1g) 0.814 0.312
Effective overall (1h) 0.914 0.221
How fast (2a) 0.839 0.196
Resume to activities (2b) 0.796 0.272
How consistent (2c) 0.830 0.167
How completely (2d) 0.886 0.164
How long (2e) 0.804 0.118
Prevents recurrence (2f) 0.737 0.086
Ease of use (2g) 0.067 0.836
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number of attacks over the 3 months to allow treat-
ment differences to manifest; however, similar
results (i.e., signiﬁcantly greater satisfaction with
naratriptan than with customary therapy) were
observed in the subanalysis of data from subjects
who experienced either less than six migraine
attacks or more than six migraine attacks.
Average pain relief scores recorded on diary
cards 4 hours post-treatment during the study 
were signiﬁcantly correlated (P < .0001, r = .18-
.51) with post-treatment responses to each PPMQ
item as well as with the total score as per Table 4,
another indication of the construct validity of the
PPMQ. Scores on the two pain-related SF-36 ques-
tions (“How much bodily pain have you had during
the past 4 weeks?” and “During the past 4 weeks,
how much did pain interfere with your normal
work?”) were signiﬁcantly correlated (P £ .002,
r = .14 - .27) with PPMQ pain items 1a (how well
the medication relieves pain), 1g (quickness of
return to usual activities after using the medication),
and 2b (how fast it allows return to usual day-to-
day activities).
Reliability
Using the CTT, all items on the PPMQ met the 
criteria for internal consistency (item-scale: r > .4),
except items 1d (r = .36) and 2g (r = .13) as indi-
cated in Table 5. At baseline, the PPMQ (with and
without items 1d and 2g) for all countries combined
resulted in a Cronbach’s alpha coefﬁcient of 0.94.
The post-trial reliability estimate was 0.96 for both
Table 3 Construct validity: detection of treatment differences*
Mean change in score
Item Naratriptan Customary therapy Difference between groups† (SE)
Pain relief (1a) 1.08 -0.10 1.18 (0.11)
Other symptoms relieved (1b) 1.27 0.00 1.27 (0.11)
Speed of relief (1c) 1.06 -0.11 1.17 (0.12)
Drowsiness (1d) 0.73 0.06 0.66 (0.10)
Length of time it works (1e) 1.27 0.10 1.17 (0.11)
No. of doses (1f) 1.51 0.07 1.44 (0.12)
Return to activities (1g) 1.43 0.14 1.29 (0.12)
Effective overall (1h) 1.42 0.04 1.38 (0.12)
How fast (2a) 0.70 0.05 0.65 (0.07)
Resume to activities (2b) 0.76 0.09 0.67 (0.07)
How consistent (2c) 0.75 -0.01 0.76 (0.07)
How completely (2d) 0.90 0.07 0.83 (0.07)
How long (2e) 0.78 0.09 0.68 (0.07)
Prevents recurrence (2f ) 0.79 0.18 0.60 (0.07)
Ease of use (2g) 0.37 0.05 0.33 (0.05)
*Mean change in scores from baseline to post-trial by PPMQ item.
†P < .001, difference between naratriptan and customary therapy for each item.
Table 4 Construct validity: correlation of average pain relief
with PPMQ items
PPMQ item Pearson correlation* N
Pain relief (1a) .50 674
Other symptoms relieved (1b) .46 671
Speed of relief (1c) .48 674
Drowsiness (1d) .30 662
Length of time it works (1e) .46 666
No. of doses (1f) .51 669
Return to activities (1g) .49 674
Effective overall (1h) .49 665
How fast (2a) .44 656
Resume to activities (2b) .46 655
How consistent (2c) .40 656
How completely (2d) .45 655
How long (2e) .40 655
Prevents recurrence (2f) .35 656
Ease of use (2g) .18 657
Total score .67 632
*P = .0001 for each PPMQ item.
PPMQ, Patient Perception of Migraine Questionnaire.
Table 5 Reliability: item-scale (Pearson) correlations*
Item Baseline Post-trial
Pain relief (1a) .83 .91
Other symptoms relieved (1b) .72 .81
Speed of relief (1c) .84 .88
Drowsiness (1d) .36 .47
Length of time it works (1e) .80 .87
No. of doses (1f) .77 .87
Return to activities (1g) .80 .86
Effective overall (1h) .87 .92
How fast (2a) .78 .84
Resume to activities (2b) .77 .81
How consistent (2c) .72 .79
How completely (2d) .80 .87
How long (2e) .68 .78
Prevents recurrence (2f) .57 .65
Ease of use (2g) .13 .46
*For internal consistency, items should demonstrate a correlation coefﬁcient
of r > .4.
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treatment groups and was consistent with or
without items 1d and 2g providing additional
support for the reliability of the PPMQ. Cronbach’s
alpha at post-trial was also very similar within each
country: Canada (0.96), Finland (0.96), the Nether-
lands (0.95), New Zealand (0.96), and Spain (0.95).
Internal consistency reliability was also con-
ﬁrmed by IRT analysis, with a marginal reliability
of 0.95 at baseline and post-trial. All of the alpha
parameters were greater than 1.0 at baseline and
post-trial (Table 6), except items 1d and 2g, indi-
cating the ability of each item to discriminate. Most
of the items other than 1d and 2g had a broad range
of beta parameter estimates indicating the ability of
each item to capture subjects with thresholds of
very high or very low satisfaction. The standard
errors ranged from 0.05 to 0.19 for each beta item
parameter estimate excluding items 1d and 2g, indi-
cating precision and item effectiveness.
Sensitivity
The PPMQ was able to discriminate between treat-
ment groups in each of the countries. The difference
between baseline and post-trial mean total scores
was not signiﬁcant (P > .1) for the customary
therapy group in any country, while they were 
signiﬁcant (P £ 0.004) for the naratriptan group in
each country as summarized in Table 7. When the
mean change in pain-severity scores (from pre-
treatment to post-trial) was graphed against mean
post-trial total PPMQ scores, the PPMQ scores
increased (improved) as the difference in severity
rating increased (improved). Differences in these
severity scores ranged from -3.0 to 3.0, with a score
above zero representing an improvement in
migraine at 4 hours post-trial. Sensitivity of the
PPMQ is represented by the positive linear slope in
Figure 1.
Table 6 Reliability: IRT analysis of alpha and beta parameter estimates at baseline and post-trial*
Baseline item parameters Post-trial item parameters
Item a b1 b2 b3 b4 b5 b6 a b1 b2 b3 b4 b5 b6
1a 4.24 -1.37 -0.45 0.39 0.55 0.95 1.77 3.34 -1.9 -0.75 0.31 0.62 1.17 2.09
1b 2.41 -1.97 -0.73 -0.08 0.49 0.94 1.85 2.00 -2.25 -0.83 -0.06 0.68 1.22 2
1c 4.21 -1.50 -0.71 0.07 0.26 0.78 1.58 2.62 -2.32 -1.08 -0.2 0.22 0.93 1.98
1d 0.72 -3.36 -1.02 -0.03 2.18 3.66 5.28 0.6 -3.09 -0.79 0.01 3.11 4.62 6.18
1e 3.14 -1.75 -0.62 0.02 0.29 0.83 1.62 2.35 -2.14 -0.82 -0.07 0.54 1.27 2.15
1f 2.70 -1.83 -0.77 -0.21 0.14 0.72 1.61 2.48 -1.97 -0.84 -0.15 0.38 0.95 1.95
1g 3.25 -1.78 -0.80 -0.14 0.09 0.72 1.47 2.16 -2.29 -0.96 -0.09 0.34 1.08 2.01
1h 5.75 -1.59 -0.59 0.05 0.21 0.62 1.28 3.93 -1.99 -0.84 0 0.37 0.92 1.72
2a 3.20 -1.86 -0.79 0.41 1.19 2.20 -2.73 -1.01 0.5 1.75
2b 2.66 -2.09 -1.09 0.26 1.23 1.88 -2.94 -1.1 0.54 1.91
2c 2.20 -2.02 -0.61 0.37 1.60 1.96 -2.48 -0.76 0.38 1.76
2d 2.96 -1.95 -0.85 0.35 1.47 2.55 -2.28 -0.77 0.47 1.85
2e 2.03 -2.16 -0.97 0.71 1.71 1.65 -2.47 -0.85 0.95 2.08
2f 1.36 -2.79 -1.11 0.04 1.47 1.28 -3.00 -1.02 0.40 1.83
2g 0.24 0.45 8.29 12.89 18.29 0.43 0.98 6.53 10.09 11.72
*a, degree of discrimination that the item provides between persons at different levels of satisfaction (a must be > 0.7 to discriminate). b, the ability of each item
to capture subjects with thresholds of very high or very low satisfaction (i.e., point at which the subject’s experience with the drug equals expectation).
Abbreviation: IRT, Item Response theory.
Table 7 Sensitivity: mean differences in baseline and post-trial scores
Mean baseline Mean change from Student’s
Treatment/country score (SE) baseline (SE) t test P > |T|
Naratriptan
Canada (n = 96) 48.85 (16.92) 9.86 (26.26) 3.68 .0004
Finland (n = 82) 48.70 (13.56) 10.04 (21.84) 4.16 .0001
The Netherlands (n = 49) 55.77 (15.55) 16.96 (20.84) 5.70 .0001
New Zealand (n = 44) 51.64 (13.62) 18.50 (20.54) 6.01 .0001
Spain (n = 47) 47.0 (16.37) 12.42 (19.53) 4.36 .0001
Customary therapy
Canada (n = 91) 49.49 (14.86) 1.66(15.53) 1.02 .31
Finland (n = 88) 49.43 (15.75) 1.42 (16.23) 0.82 .41
The Netherlands (n = 43) 53.27 (16.16) -2.60 (13.82) -1.24 .22
New Zealand (n = 40) 57.67 (18.35) 0.20 (18.23) 0.07 .95
Spain (n = 52) 47.41 (16.64) -4.11 (17.56) -1.69 .10
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Scoring
Item-scale correlations ranged between 0.57 and
0.87 with the exception of items 1d (0.36) and 2g
(0.13) suggesting that these two items should be
excluded from scoring. With the exception of these
two items, these results provide strong empirical
support that each item contributes roughly equal
and substantial proportions of information to the
total scale score and therefore no weighting is
required. Responses to each item are not weighted
and are simply summed to yield a total score with
a range of 15 to 91. Higher scores indicate greater
satisfaction.
Discussion
This study demonstrates that the PPMQ, with some
reﬁnements to the questionnaire, measures patient
satisfaction with migraine treatment both reliably
and validly. Internal consistency reliability for the
PPMQ (0.96) far exceeded the standard of 0.70
generally applied to self-reported instruments used
for group assessment of health-related quality of life
[7]. For an individual assessment, the standard for
internal consistency reliability is 0.9, which would
allow physicians to assess individual patients in
terms of patient preference and satisfaction for a
given migraine therapy in a clinical setting [13,14].
The principal components factor analysis with
varimax rotation revealed that the satisfaction sub-
scale was conceptually distinct, with the exception
of items 1d and 2g. The questionnaire was able to
detect score differences between the two treatment
groups. The degree of sensitivity or responsiveness
was consistent within each country and consistently
measured a minimal mean difference of 9 points in
detecting differences between the treatment groups
in this study.
Face validity shows that the following pairs of
items in the PPMQ are similarly worded: 1c, how
fast the medication relieves migraine pain and other
migraine symptoms; 2a, how fast it starts to relieve
migraine pain; 1a, how well the medication relieves
pain; 1h, how effective the medication is overall at
relieving migraine pain and other migraine symp-
toms; 1e, how long the medication works; 2e, how
long it relieves migraine pain; 1g, quickness of
return to usual activities after using the medication;
and 2b, how fast it allows return to usual day-
to-day activities. Similarly worded items did not
appear sequentially in the questionnaire, however,
which may account for local dependence not being
violated in the IRT analysis as well as for the high
estimates of internal consistency reliability. Because
face validity suggests redundancy, and item-scale
correlations were high for these item pairs, we
would therefore recommend that four items (1h, 2a,
2b, and 2e) be dropped from future versions of the
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Figure 1 Mean PPMQ total post-trial scores (range, 15–91) versus mean change in pain severity scores from patient diaries.
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PPMQ. These four items were chosen because each
had a lower alpha (discriminatory) IRT parameter
compared to its corresponding similarly worded
item.
Moderately signiﬁcant correlations were
observed between the clinical efﬁcacy of naratrip-
tan and satisfaction with this therapy (r = .46 - .51),
despite the limitations of having to compare a 4-
point pain severity scale from patient diaries with
the 7-point Likert-type scale in the PPMQ or a
generic quality of life scale (SF-36) with a migraine-
speciﬁc satisfaction scale. The pain items in the SF-
36 also reﬂected only the last 4 weeks of the trial,
whereas no time limits were stated in the PPMQ.
The analysis concludes that 13 of the 15 items
on the PPMQ constitute a unidimensional item
pool, excluding items 1d (how drowsy the medica-
tion makes you) and 2g (ease of use). The PPMQ
was initially developed to provide a pool of ques-
tions, which would cover attributes of any given
migraine drug in terms of satisfaction. Despite the
overall success of the PPMQ, these two items did
not perform well in this study. Drowsiness was not
a common side effect of naratriptan (the only
triptan available at the time) nor was it for many of
the customary therapies seen in this trial, which
may explain why this item did not discriminate.
Because additional triptans are now available, pos-
sibly with different side-effect proﬁles, a new item
will be added to the PPMQ that attempts to assess
satisfaction with side effects other than drowsiness,
and this version will be piloted in future studies.
Item 2g (ease of use) was included on the question-
naire to capture preference for a given dosing
regimen. Because the majority of dosage forms for
this trial were oral tablets, this item did not dis-
criminate among individuals in terms of a prefer-
ence for a given formulation. However, item 2g
would provide versatility for use in future trials that
may include other dosage forms, such as nasal
sprays or injectables. Alternatively, both of these
items may be important constructs and could be
retained as optional items to be reported separately
and not scored.
Item 2f (how consistently it prevents my migraine
from coming back) could be further reﬁned.
Although the item loaded at 0.737 on factor 1 in
the principal component factor analysis, the item-
scale correlations were 0.57 at baseline and 0.65 at
post-trial. Although the item does reﬂect a marginal
improvement at post-trial, the reason for the mod-
erate estimates may be that only a subset of patients
experienced recurrence: 26% of attacks treated
with naratriptan and 28% of attacks treated with
customary therapy. This assertion cannot be empir-
ically tested because the study was a multiattack
study and recurrence does not occur with every
migraine attack. The word “recurrence” was pur-
posefully not chosen when the PPMQ was devel-
oped initially because the term is ambiguous and
could be deﬁned differently by different individuals.
A possible solution might be to add a response 
of N/A (not applicable), which would exclude 
those individuals who do not have recurrent
migraines.
Interpretation of the study results may be con-
founded by the study design, the frequency of
migraine attacks, the severity of individual attacks,
and recall bias. Although the trial was randomized,
subjects could not be blinded because of inclusion
of different formulations and drugs in the custom-
ary therapy group and acute dosing restrictions for
naratriptan. Because this was an open-label trial,
bias may have occurred in the customary therapy
group, resulting in overestimation of item-scale cor-
relations. No subgroup analyses were performed
within the customary therapy group because the
sample size was too small for each class of drugs.
Consequently, the data did not allow for control of
within treatment differences for the customary
therapy group.
Recall bias on the PPMQ questionnaire may have
occurred because of the 3-month clinical trial time
frame. Most subjects in each of the treatment
groups reported more than one headache during the
trial, and headache severity often varied for indi-
viduals. Responses to the PPMQ may reﬂect satis-
faction with drug therapy for the most severe
headaches rather than a composite of all of the
headaches experienced. However, the bias should
have been nondifferential, because it would be
expected to have occurred in both treatment
groups.
In summary, the results of this ﬁve-country study
indicate that the PPMQ is both valid and reliable.
For future studies, we recommend some minor
modiﬁcations to the questionnaire, including addi-
tion of one item (side effects) and deletion of several
redundant items.
Permission to use the PPMQ, copyrighted by
GlaxoWellcome, may be obtained at no cost by con-
tacting Kimberly Hunt Davis at GlaxoSmithKline.
The authors thank Rose Mills for assistance in writing
the manuscript.
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Appendix A
Summarized Version of the PPMQ
1a. How well the medication relieves pain
1b. How well the medication relieves other
migraine symptoms
1c. How fast the medication relieves migraine pain
and other migraine symptoms
1d. How drowsy the medication makes you feel
1e. How long the medication works
1f. Number of doses needed for relief of symptoms
1g. Quickness of return to usual activities after
using the medication
1h. How effective the medication is overall at
relieving migraine pain and other migraine
symptoms
2a. How fast it starts to relieve migraine pain
2b. How fast it allows return to usual day-to-day
activities
2c. How consistently it relieves migraine pain
2d. How completely it relieves migraine pain
2e. How long it relieves migraine pain
2f. How consistently it prevents migraine pain
from coming back
2g. How easy it is to use
